Treatments using transgenic goat produced antithrombin III
First Claim
Patent Images
1. A method of treating a subject having an ATIII deficiency or inflammation, comprising:
- administering to the subject goat mammary gland produced antithrombin III having a monosaccharide composition which comprises a higher level of mannose than plasma derived antithrombin III, wherein thrombin is inhibited.
6 Assignments
0 Petitions
Accused Products
Abstract
This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.
-
Citations
10 Claims
-
1. A method of treating a subject having an ATIII deficiency or inflammation, comprising:
administering to the subject goat mammary gland produced antithrombin III having a monosaccharide composition which comprises a higher level of mannose than plasma derived antithrombin III, wherein thrombin is inhibited. - View Dependent Claims (2, 3, 4, 5, 6)
-
7. A method of treating inflammation in a subject, comprising:
administering to the subject a Moat mammary gland produced antithrombin III having a monosaccharide composition which comprises a higher level of mannose than plasma derived antithrombin III, wherein thrombin is inhibited. - View Dependent Claims (8, 9, 10)
Specification